An observational study in Advanced Lymphoma, Refractory Lymphoma and Refractory Leukemia, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by Medical University of Vienna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice
310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.
This study's planned enrollment of 150 is below the median of 200 across 29 observational studies indexed under Lymphoma, T-Cell.
Browse Lymphoma, T-Cell studies →Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Compared within Lymphoma, T-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
150 patients with relapsed/ refractory acute leukemia and relapsed/ refractory aggressive lymphoma after standard treatment fulfilling inclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Next generation functional drug screening · Diagnostic Test: Comprehensive genomic profiling
Diagnostic Test: Next generation functional drug screening · Diagnostic Test: Comprehensive genomic profiling
Diagnostic Test: Next generation functional drug screening · Diagnostic Test: Comprehensive genomic profiling
High-throughput image based in-vitro drug screening on primary patient tumor cells
Comprehensive targeted profiling of genetic aberrations on primary patient tumor material
Also known as: FoundationOne Heme
Percentage of patients with a ratio ≥1.3 of progression free survival (PFS) compared to most recent treatment
The study aims to identify if next-generation functional drug screening (ngFDS) and/or comprehensive genomic profiling (CGP; FoundationOne®Heme) compared to physicians' choice guided treatment will have an increased percentage of patients with a ratio ≥1.3 of progression free survival (PFS)/PFS of most recent treatment in patients with aggressive haematological malignancies
Time frame: Through study completion, an average of 8 month
Average Ratio of PFS/PFS of most prior treatment
Average Ratio of PFS/PFS of most prior treatment
Time frame: Through study completion, an average of 8 months
Overall response rate (ORR)
Overall response rate (ORR)
Time frame: Through study completion, an average of 8 months
Number of treatable targets identified
Number of treatable targets identified
Time frame: Through study completion, an average of 8 months
Plan to share: No
Started Jun 2020 (actual). Primary completion is estimated for Mar 2026, 69 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →